Transition rates between amyloid and neurodegeneration biomarker states and to dementia: A population-based, longitudinal cohort study

The Lancet Neurology

Volumn 15, Issue 1, 2016, Pages 56-64

  Jack, Clifford R ^a   Therneau, Terry M ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Knopman, David S ^a   Lowe, Val J ^a   Mielke, Michelle M ^a   Vemuri, Prashanthi ^a   Roberts, Rosebud O ^a   Machulda, Mary M ^a   Senjem, Matthew L ^a   Gunter, Jeffrey L ^a   Rocca, Walter A ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; FLUORODEOXYGLUCOSE F 18; BIOLOGICAL MARKER;

ADULT; AGED; AGING; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; COGNITIVE DYSFUNCTION; CROSS-SECTIONAL STUDY; DISEASE COURSE; HEALTH SURVEY; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID; PSYCHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; COGNITIVE DYSFUNCTION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PLAQUE, AMYLOID; POPULATION SURVEILLANCE;

EID: 84947318181     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00323-3     Document Type: Article

References (34)

1. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014, 13:614-629.
2. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 2011, 7:270-279.
3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Awlzheimer's Assocation Workgroup. Alzheimers Dement 2011, 7:263-269.
4. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Assocation workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
5. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC Tau imaging: early progress and future directions. Lancet Neurol 2015, 14:114-124.
6. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015, published online Sept 7. 10.1002/ana.24517.
7. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to NIA-AA crtiteria for preclinical Alzheimer's disease. Ann Neurol 2012, 71:765-775.
8. Jack CR, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014, 13:997-1005.
9. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008, 30:58-69.
10. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
11. Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage 2005, 26:600-608.
12. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009, 19:497-510.
13. Jack CR, Wiste HJ, Weigand S, et al. Different definitions of neurodegeneration produce similar frequencies of amyloid and neurodegeneration biomarker groups by age among cognitively non-impaired individuals. Brain 2015, published online Sept 30. http://dx.doi.org/10.1093/brain/awv283.
14. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997, 49:786-794.
15. Barnes J, Ridgway GR, Bartlett J, et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance?. Neuroimage 2010, 53:1244-1255.
16. Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 2015, 138:1370-1381.
17. Jackson C Multi-state models for panel data: The msm Package for R. Stat Soft 2011, 38:1-28.
18. St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, Rocca WA Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc 2012, 87:151-160.
19. Knopman DS, Jack CR, Wiste HJ, et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 2013, 73:472-480.
20. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol 2011, 121:571-587.
21. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 2009, 18:691-701.
22. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 2014, 128:755-766.
23. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB Brain changes in older adults at very low risk for Alzheimer's disease. J Neurosci 2013, 33:8237-8242.
24. Jagust W Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 2013, 77:219-234.
25. Knopman DS, Jack CR, Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol 2013, 70:1030-1038.
26. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012, 71:362-381.
27. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
28. Jack CR, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
29. Bertens D, Knol DL, Scheltens P, Visser PJ Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. Alzheimers Dement 2015, 11:511-522.
30. Yau WY, Tudorascu DL, McDade EM, et al. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurol 2015, 14:804-813.
31. Villain N, Chetelat G, Grassiot B, et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012, 135:2126-2139.
32. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367.
33. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015, 313:1924-1938.
34. Jack CR, Wiste HJ, Weigand SD, et al. Age, Sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol 2015, 72:511-519.